25 julio 2023

SMALL-CELL LUNG CANCER / MIRADA A FUTURO . Las 10 Principales Farmacéuticas Según el Informé de Investigación de Mercado Global Terapéutico del Cáncer de Pulmón de Células Pequeñas : GlaxoSmithKline, Bristol-Myers Squibb, Sanofi, Menarini, ZIOPHARM Oncology, Sun Pharmaceuticals Industries, Takeda Pharmaceutical, Merck, Novartis, Amgen . ...


 Joseph WatsonJuly 25, 2023 .


New Jersey, United States – The Global Small Cell Lung Cancer Therapeutics Market is comprehensively and accurately detailed in the report, taking into consideration various factors such as competition, regional growth, segmentation, and market size by value and volume. This is an excellent research study specially compiled to provide the latest insights into critical aspects of the Global Small Cell Lung Cancer Therapeutics market. The report includes different market forecasts related to market size, production, revenue, consumption, CAGR, gross margin, price, and other key factors. It is prepared with the use of industry-best primary and secondary research methodologies and tools. It includes several research studies such as manufacturing cost analysis, absolute dollar opportunity, pricing analysis, company profiling, production and consumption analysis, and market dynamics.

The competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light on the competitive scenario of the Global Small Cell Lung Cancer Therapeutics market to know the competition at both the domestic and global levels. Market experts have also offered the outline of every leading player of the Global Small Cell Lung Cancer Therapeutics market, considering the key aspects such as areas of operation, production, and product portfolio. 


Additionally, companies in the report are studied based on key factors such as company size, market share, market growth, revenue, production volume, and profits .

Leading 10 Companies in the Global Small Cell Lung Cancer Therapeutics Market Research Report :


GlaxoSmithKline, Bristol-Myers Squibb, Sanofi, Menarini, ZIOPHARM Oncology, Sun Pharmaceuticals Industries, Takeda Pharmaceutical, Merck, Novartis, Amgen . ...



IAG Ganará 562M€ en el Segundo Trimestre, el 322,6% Más . El Mercado Espera una Revisión al Alza de las Guías de Beneficio Operativo .


SE ESPERAN REVISIONES ALCISTAS EN LAS PERSPECTIVAS PARA FINAL DE AÑO .


JOSÉ JIMÉNEZ 

La Recuperación del Tráfico Aéreo y el efecto de la Fuerte Demanda Acumulada Impulsarán el Beneficio Neto de International Consolidated Airlines Group (IAG) Hasta los 562 Millones de euros, Según las Previsiones del Consenso de Bloomberg Consultadas por finanzas.com.

La Cifra supone un 322 por ciento más que los 133 millones de beneficio neto que el grupo reportó en el mismo periodo del año anterior, y está en línea con el incremento de las ganancias pronosticado por la IATA, la patronal del sector .

Además, IAG alcanzará unas ventas de 7.351 millones de euros, el 24 por ciento más que los 5.916 millones facturados el año anterior.

En cuanto al Beneficio Operativo (ebit), la métrica más seguida por los analistas, IAG reportará un total de 884 millones de euros, lo que supone un incremento del 200 por ciento en comparación con el mismo periodo del 2022 . ...